Activity
-
"My dream is that all the money that we raised, all the years of building this machine, will be translated to help people like my co-founder, Louis'…
"My dream is that all the money that we raised, all the years of building this machine, will be translated to help people like my co-founder, Louis'…
Liked by Ansuman Satpathy
-
I am proud to announce that Dren Bio has entered into a collaboration agreement with Novartis to utilize our Targeted Myeloid Engager and…
I am proud to announce that Dren Bio has entered into a collaboration agreement with Novartis to utilize our Targeted Myeloid Engager and…
Liked by Ansuman Satpathy
-
It's new paper time at John DiPersio's lab, now available in First Edition at Blood Advances. In this one, we optimize an anti-CD47/cKit based…
It's new paper time at John DiPersio's lab, now available in First Edition at Blood Advances. In this one, we optimize an anti-CD47/cKit based…
Liked by Ansuman Satpathy
Experience
Education
More activity by Ansuman
-
Just in time in advance of the long holiday weekend, the July edition of The Immuno-Oncology Digest is here, featuring PICI Network updates, industry…
Just in time in advance of the long holiday weekend, the July edition of The Immuno-Oncology Digest is here, featuring PICI Network updates, industry…
Liked by Ansuman Satpathy
-
Developing safe and effective treatment for patients with autoimmune and inflammatory disease remains a significant unmet challenge in medicine. We…
Developing safe and effective treatment for patients with autoimmune and inflammatory disease remains a significant unmet challenge in medicine. We…
Liked by Ansuman Satpathy
-
Congrats to our newest portfolio company Santa Ana Bio, Inc. on their launch! “We’ve been drugging lots of cytokines, trying to modify the biology…
Congrats to our newest portfolio company Santa Ana Bio, Inc. on their launch! “We’ve been drugging lots of cytokines, trying to modify the biology…
Liked by Ansuman Satpathy
-
Cartography is excited to announce our first partnership with Gilead in LUAD and TNBC to identify and develop therapies against novel targets and…
Cartography is excited to announce our first partnership with Gilead in LUAD and TNBC to identify and develop therapies against novel targets and…
Liked by Ansuman Satpathy
-
Exited to announce this partnership between Cartography Biosciences and Gilead Sciences! I'm looking forward to working with them as we discover and…
Exited to announce this partnership between Cartography Biosciences and Gilead Sciences! I'm looking forward to working with them as we discover and…
Liked by Ansuman Satpathy
-
Proud to share we co-led OverT Bio's seed to make cell therapies suck less! From day 0 it has been a delightful mind meld with founders, Mat Legut…
Proud to share we co-led OverT Bio's seed to make cell therapies suck less! From day 0 it has been a delightful mind meld with founders, Mat Legut…
Liked by Ansuman Satpathy
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Ansuman Satpathy
-
Ansuman Satpathy
Cloud Big Data Architect | Azure| AWS | Big data -Hadoop , Hive , PySpark on Databricks | Oracle 10g Professional Certified | PowerBI | Tableau
-
Ansuman Satpathy
Consultant at Deloitte USI
-
Ansuman Satpathy
-
Ansuman Tapan Satpathy
8 others named Ansuman Satpathy are on LinkedIn
See others named Ansuman Satpathy